This CPB has been revised to: (i) add the subtypes of peripheral T-cell lymphoma (PTCL) for which treatment with pralatrexate is considered medically necessary; (ii) reword the continuation of therapy criteria; (iii) state that pralatrexate considered experimental and investigational for the treatment of esophagogastric cancer.